Cervical cancer: guideline history

Standard of care today →

2 dated versions from 2021 to 2024 listing 4 changes. Pick two versions to see what changed between them; the timeline below shows every version with the event it is anchored to.

From (exclusive)To (inclusive)

+2 added0 removed↔ 0 recategorisedacross 1 version

Added
Locally advanced, FIGO III-IVA
Pembrolizumab with cisplatin-based chemoradiation and continued for up to 2 years.
Pembrolizumab KEYNOTE-A18 / ENGOT-cx11 / GOG-3047
Added
Locally advanced
Six weeks of induction carboplatin-paclitaxel before chemoradiation as an option (INTERLACE).
Carboplatin Paclitaxel / nab-paclitaxel INTERLACE

Timeline

2021-10NCCN2021 updates
Anchored to: FDA accelerated approval of tisotumab vedotin (September 2021) and approval of pembrolizumab with chemotherapy for PD-L1 CPS 1 or above (October 2021, KEYNOTE-826)
- addedRecurrent or metastatic, first line, PD-L1 CPS 1 or above: Pembrolizumab with platinum-paclitaxel, with or without bevacizumab, as the preferred first-line regimen.
- addedRecurrent or metastatic, second line: Tisotumab vedotin after chemotherapy; confirmed by innovaTV 301 in 2024.
2024-10NCCN2024 updates
Anchored to: FDA approval of pembrolizumab with chemoradiation for FIGO 2014 stage III-IVA disease (January 2024, KEYNOTE-A18); INTERLACE publication (Lancet, October 2024)
- addedLocally advanced, FIGO III-IVA: Pembrolizumab with cisplatin-based chemoradiation and continued for up to 2 years.
- addedLocally advanced: Six weeks of induction carboplatin-paclitaxel before chemoradiation as an option (INTERLACE).

Other cancers

Acute myeloid leukaemia Bladder & urothelial cancer Chronic lymphocytic leukaemia Colorectal cancer Diffuse large B-cell lymphoma Endometrial cancer Gastric & gastro-oesophageal junction cancer Hepatocellular carcinoma HER2-positive breast cancer HR-positive / HER2-negative breast cancer Melanoma Multiple myeloma Non-small-cell lung cancer Oesophageal cancer Ovarian cancer Prostate cancer Renal cell carcinoma Triple-negative breast cancer (TNBC)

Each entry is anchored to a dated public event and links to the guideline body’s page for the disease; NCCN “Summary of changes” pages sit behind a free login and are not reproduced. Version labels say “update” where the NCCN version number has not been verified. Corrections are welcome via the repository.